SGLT2 Inhibitors Improve Skeletal Muscle Pathology in Heart Failure, reveals study
Patients with heart failure and reduced ejection fraction (HFrEF) often experience skeletal muscle pathology, contributing to symptoms and reduced quality of life. While sodium–glucose cotransporter 2 inhibitors (SGLT2i) have shown clinical benefits in HFrEF, their effects on skeletal muscle remain unclear. A recent study aimed to investigate whether SGLT2i influences skeletal muscle pathology in patients […]